Loading stock data…
TransCode Therapeutics, Inc. (RNAZ)
$1.89-0.17 (-8.25%)
Market ClosedLast close Sep 8
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransCode Therapeutics, Inc. in the Healthcare sector is trading at $1.89 with a market capitalization of $2M. The stock is currently near its 52-week low of $1.83, remaining 74.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.21M↑ | -$17.62M↓ | -$6.49M↓ | -$4.54M↓ | -$4.07M |
| Net Income | -$6.75M↑ | -$17.79M↓ | -$13.44M↓ | -$4.86M↓ | -$4.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of pati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.96%
Volume
Today's trading volume
37,454
Recent News
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138. It met its primary safety objectives and demonstrated durable disease stabilization in patients with advanced metastatic cancer. The Boston-based clinical-stage company announced Wednesday that the drug candidate was well-tolerated, showing a complete absence of dose-limiting toxicities across all tested
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea
TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life Sciences
TransCode Therapeutics (RNAZ) said Wednesday it has agreed to buy biotechnology immuno-oncology comp